<p><a href="https://www.ncbi.nlm.nih.gov/gene/7468">NSD2</a> p.E1099K (EK) is a mutation shown to be enriched in patients that relapse with pediatric Acute Lymphoblastic Leukemia (ALL). This work aims to uncover 3D chromatin architecture-related mechanisms responsible for drug resistance or therapy failure in these patients. We investigated this by performing Hi-C, ATAC-Seq, and RNA-Seq on three B-ALL cell lines heterozygous for EK either expressing a <a href="https://www.ncbi.nlm.nih.gov/gene/7468">NSD2</a> targeting small RNA (sRNA) or a non-targeting small hairpin RNAs (shRNA). We also performed RNA-Seq on three matched diagnosis/relapse B-ALL samples with the relapse enriched EK mutation. </p>

NSD2 E1099K Drives Relapse in Pediatric Acute Lymphoblastic Leukemia by    Disrupting 3D Chromatin Organization

1 selected publication including "The NSD2 p.E1099K Mutation Is Enriched at Relapse and Confers Drug Res..." (22 citations)

NSD2 E1099K Drives Relapse in Pediatric Acute Lymphoblastic Leukemia by Disrupting 3D Chromatin Organization

The NSD2 p.E1099K Mutation Is Enriched at Relapse and Confers Drug Resistance in a Cell Context–Dependent Manner in Pediatric Acute Lymphoblastic Leukemia